Oxford Nanopore Technologies used the Jefferies Global Healthcare Conference on Tuesday, 17 November 2026, to outline a narrower commercial strategy. Chief Executive Gordon Sanghera said the company is focusing on fewer, higher-value applications while still facing competition, execution demands and a long path to scale.

Sanghera said the narrower focus does not shrink the opportunity. "By doing so, the opportunity doesn't become smaller, it becomes more focused. Our choices are becoming clearer," he said.

The company named four priorities: customer-centric growth in high-value applications, a simpler product portfolio, disciplined execution with tighter cost control, and a high-performance culture with clearer accountability.

Management reported margin gains. Consumables margins rose from 64% in 2023 to about 75%. Devices and services margins rose from 23% to 34%. The company attributed the gains to pricing changes, better yield, flow cell recycling and scale. It targets consumables margins of 80% or more over time.

Management expects adjusted EBITDA break-even in 2027, positive free cash flow from 2028 and revenue above $700 million by 2030. A cross-licensing agreement with a diagnostics company brings $20 million upfront in 2026, along with product sales and royalties over time.

Research currently accounts for about two-thirds of revenue, with applied markets such as biopharma and diagnostics making up about one-third. The company expects clinical and biopharma applications to represent about two-thirds of revenue by 2030. Executives said competition is rising in long-read sequencing, but they believe the technology remains differentiated in selected applications.

Shares were last at $201, down 1.57% from the previous close of $204.2, according to the report. The 52-week range was $95.7 to $239.4. The article cites InvestingPro data showing a 53% return over six months and a Fair Value analysis suggesting the stock may be undervalued. Those are data-provider claims, not company statements.